Modified stoke ankylosing spondylitis spinal score as an outcome measure to assess the impact of treatment on structural progression in ankylosing spondylitis

Désirée van der Heijde, Jürgen Braun, Atul Deodhar, Xenofon Baraliakos, Robert Landewé, Hanno B Richards, Brian Porter, Aimee Readie, Désirée van der Heijde, Jürgen Braun, Atul Deodhar, Xenofon Baraliakos, Robert Landewé, Hanno B Richards, Brian Porter, Aimee Readie

Abstract

In ankylosing spondylitis (AS), structural damage that occurs as a result of syndesmophyte formation and ankylosis of the vertebral column is irreversible. Structural damage is currently assessed by conventional radiography and scoring systems that reliably assess radiographic structural damage are needed to capture the differential effects of drugs on structural damage progression. The validity of the modified Stoke Ankylosing Spondylitis Spinal Score (mSASSS) as a primary outcome measure in evaluating the effect of AS treatments on radiographic progression rates was assessed in this review. The mSASSS has not been used, to date, as a primary outcome measure in a prospective randomized controlled clinical trial of biologic therapy in AS. This review of the medical literature confirmed that the mSASSS is the most validated and widely used method for assessing radiographic progression in AS, correlating with worsening measures of disease signs and symptoms, spinal mobility and physical function, with a 2-year interval being required to ensure sufficient sensitivity to change.

Keywords: ankylosing spondylitis; imaging; mSASSS; radiograph; radiography; scoring; spondyloarthritis.

© The Author(s) 2018. Published by Oxford University Press on behalf of the British Society for Rheumatology.

Figures

Fig . 1
Fig. 1
Sample mSASSS scoring (from 0 to 3) for spinal vertebral edges Reproduced from imaging of axial spondyloarthritis including ankylosing spondylitis, J Braun & X Baraliakos, Ann Rheum Dis 70(Suppl 1): i97–i103, 2011. With permission from BMJ Publishing Group Ltd.

References

    1. Landewé R, Dougados M, Mielants H, van der Tempel H, van der Heijde D.. Physical function in ankylosing spondylitis is independently determined by both disease activity and radiographic damage of the spine. Ann Rheum Dis 2009;68:863–7.
    1. Baraliakos X, Listing J, Rudwaleit M. et al. Progression of radiographic damage in patients with ankylosing spondylitis: defining the central role of syndesmophytes. Ann Rheum Dis 2007;66:910–5.
    1. Ostergaard M, Lambert RG.. Imaging in ankylosing spondylitis. Ther Adv Musculoskelet Dis 2012;4:301–11.
    1. Ramiro S, van Tubergen A, van der Heijde D. et al. Brief report: erosions and sclerosis on radiographs precede the subsequent development of syndesmophytes at the same site: a twelve-year prospective followup of patients with ankylosing spondylitis. Arthritis Rheumatol 2014;66:2773–9.
    1. Baraliakos X, Heldmann F, Callhoff J. et al. Which spinal lesions are associated with new bone formation in patients with ankylosing spondylitis treated with anti-TNF agents? A long-term observational study using MRI and conventional radiography. Ann Rheum Dis 2014;73:1819–25.
    1. Maksymowych WP, Morency N, Conner-Spady B, Lambert RG.. Suppression of inflammation and effects on new bone formation in ankylosing spondylitis: evidence for a window of opportunity in disease modification. Ann Rheum Dis 2013;72:23–8.
    1. Machado PM, Baraliakos X, van der Heijde D, Braun J, Landewé R.. MRI vertebral corner inflammation followed by fat deposition is the strongest contributor to the development of new bone at the same vertebral corner: a multilevel longitudinal analysis in patients with ankylosing spondylitis. Ann Rheum Dis 2016;75:1486–93.
    1. Dougados M, Sepriano A, Molto A. et al. Sacroiliac radiographic progression in recent onset axial spondyloarthritis: the 5-year data of the DESIR cohort. Ann Rheum Dis 2017;76:1823–8.
    1. Ramiro S, van der Heijde D, van Tubergen A. et al. Higher disease activity leads to more structural damage in the spine in ankylosing spondylitis: 12-year longitudinal data from the OASIS cohort. Ann Rheum Dis 2014;73:1455–61.
    1. MacKay K, Mack C, Brophy S, Calin A.. The Bath Ankylosing Spondylitis Radiology Index (BASRI): a new, validated approach to disease assessment. Arthritis Rheum 1998;41:2263–70.
    1. Averns HL, Oxtoby J, Taylor HG. et al. Radiological outcome in ankylosing spondylitis: use of the Stoke Ankylosing Spondylitis Spine Score (SASSS). Br J Rheumatol 1996;35:373–6.
    1. Creemers MC, Franssen MJ, van't Hof MA. et al. Assessment of outcome in ankylosing spondylitis: an extended radiographic scoring system. Ann Rheum Dis 2005;64:127–9.
    1. Baraliakos X, Listing J, Rudwaleit M, Sieper J, Braun J.. Development of a radiographic scoring tool for ankylosing spondylitis only based on bone formation: addition of the thoracic spine improves sensitivity to change. Arthritis Rheum 2009;61:764–71.
    1. Mahmoud I, Gafsi L, Saidane O. et al. Limit of the available spine radiologic scoring methods in ankylosing spondylitis when the facet joint is the only structure involved. Egyptian Rheumatol 2016;38:203–7.
    1. de Vlam K, Mielants H, Veys EM.. Involvement of the zygapophyseal joint in ankylosing spondylitis: relation to the bridging syndesmophyte. J Rheumatol 1999;26:1738–45.
    1. Baraliakos X, Landewé R, Hermann KG. et al. Inflammation in ankylosing spondylitis: a systematic description of the extent and frequency of acute spinal changes using magnetic resonance imaging. Ann Rheum Dis 2005;64:730–4.
    1. Ramiro S, van Tubergen A, Stolwijk C. et al. Scoring radiographic progression in ankylosing spondylitis: should we use the modified Stoke Ankylosing Spondylitis Spine Score (mSASSS) or the Radiographic Ankylosing Spondylitis Spinal Score (RASSS)? Arthritis Res Ther 2013;15:R14.
    1. Wanders AJ, Landewé RB, Spoorenberg A. et al. What is the most appropriate radiologic scoring method for ankylosing spondylitis? A comparison of the available methods based on the Outcome Measures in Rheumatology Clinical Trials filter. Arthritis Rheum 2004;50:2622–32.
    1. van der Heijde D, Landewe R.. Selection of a method for scoring radiographs for ankylosing spondylitis clinical trials, by the Assessment in Ankylosing Spondylitis Working Group and OMERACT. J Rheumatol 2005;32:2048–9.
    1. Maas F, Arends S, Brouwer E. et al. Incorporating assessment of the cervical facet joints in the modified Stoke ankylosing spondylitis spine score is of additional value in the evaluation of spinal radiographic outcome in ankylosing spondylitis. Arthritis Res Ther 2017;19:77.
    1. Bruynesteyn K, Boers M, Kostense P, van der Linden S, van der Heijde D.. Deciding on progression of joint damage in paired films of individual patients: smallest detectable difference or change. Ann Rheum Dis 2005;64:179–82.
    1. Landewé R, van der Heijde D.. Radiographic progression depicted by probability plots: presenting data with optimal use of individual values. Arthritis Rheum 2004;50:699–706.
    1. Spoorenberg A, de Vlam K, van der Linden S. et al. Radiological scoring methods in ankylosing spondylitis. Reliability and change over 1 and 2 years. J Rheumatol 2004;31:125–32.
    1. Wanders A, Landewé R, Spoorenberg A. et al. Scoring of radiographic progression in randomised clinical trials in ankylosing spondylitis: a preference for paired reading order. Ann Rheum Dis 2004;63:1601–4.
    1. Bland JM, Altman DG.. Statistical methods for assessing agreement between two methods of clinical measurement. Lancet 1986;1:307–10.
    1. Ramiro S, Stolwijk C, van Tubergen A. et al. Evolution of radiographic damage in ankylosing spondylitis: a 12 year prospective follow-up of the OASIS study. Ann Rheum Dis 2015;74:52–9.
    1. Braun J, Baraliakos X, Deodhar A. et al. Effect of secukinumab on clinical and radiographic outcomes in ankylosing spondylitis: 2-year results from the randomised phase III MEASURE 1 study. Ann Rheum Dis 2017;76:1070–7.
    1. Maas F, Spoorenberg A, Brouwer E. et al. Spinal radiographic progression in patients with ankylosing spondylitis treated with TNF-α blocking therapy: a prospective longitudinal observational cohort study. PLoS One 2015;10:e0122693.
    1. Baraliakos X, Listing J, von der Recke A, Braun J.. The natural course of radiographic progression in ankylosing spondylitis–evidence for major individual variations in a large proportion of patients. J Rheumatol 2009;36:997–1002.
    1. Maas F, Arends S, Brouwer E. et al. Reduction in spinal radiographic progression in ankylosing spondylitis patients receiving prolonged treatment with tumor necrosis factor inhibitors. Arthritis Care Res 2017;69:1011–9.
    1. Wanders A, Heijde D, Landewé R. et al. Nonsteroidal antiinflammatory drugs reduce radiographic progression in patients with ankylosing spondylitis: a randomized clinical trial. Arthritis Rheum 2005;52:1756–65.
    1. Sieper J, Listing J, Poddubnyy D. et al. Effect of continuous versus on-demand treatment of ankylosing spondylitis with diclofenac over 2 years on radiographic progression of the spine: results from a randomised multicentre trial (ENRADAS). Ann Rheum Dis 2016;75:1438–43.
    1. Poddubnyy D, Haibel H, Listing J. et al. Baseline radiographic damage, elevated acute-phase reactant levels, and cigarette smoking status predict spinal radiographic progression in early axial spondylarthritis. Arthritis Rheum 2012;64:1388–98.
    1. van der Heijde D, Landewé R, Einstein S. et al. Radiographic progression of ankylosing spondylitis after up to two years of treatment with etanercept. Arthritis Rheum 2008;58:1324–31.
    1. Braun J, Baraliakos X, Hermann KG. et al. The effect of two golimumab doses on radiographic progression in ankylosing spondylitis: results through 4 years of the GO-RAISE trial. Ann Rheum Dis 2014;73:1107–13.
    1. van der Heijde D, Landewé R, Baraliakos X. et al. Radiographic findings following two years of infliximab therapy in patients with ankylosing spondylitis. Arthritis Rheum 2008;58:3063–70.
    1. van der Heijde D, Salonen D, Weissman BN. et al. Assessment of radiographic progression in the spines of patients with ankylosing spondylitis treated with adalimumab for up to 2 years. Arthritis Res Ther 2009;11:R127.
    1. Baraliakos X, Listing J, Rudwaleit M. et al. Radiographic progression in patients with ankylosing spondylitis after 2 years of treatment with the tumour necrosis factor alpha antibody infliximab. Ann Rheum Dis 2005;64:1462–6.
    1. Baraliakos X, Listing J, Brandt J. et al. Radiographic progression in patients with ankylosing spondylitis after 4 yrs of treatment with the anti-TNF-alpha antibody infliximab. Rheumatology 2007;46:1450–3.
    1. Kroon F, Landewé R, Dougados M, van der Heijde D.. Continuous NSAID use reverts the effects of inflammation on radiographic progression in patients with ankylosing spondylitis. Ann Rheum Dis 2012;71:1623–9.
    1. Poddubnyy D, Rudwaleit M, Haibel H. et al. Effect of non-steroidal anti-inflammatory drugs on radiographic spinal progression in patients with axial spondyloarthritis: results from the German Spondyloarthritis Inception Cohort. Ann Rheum Dis 2012;71:1616–22.
    1. Sepriano A, Regel A, van der Heijde D. et al. Efficacy and safety of biological and targeted-synthetic DMARDs: a systematic literature review informing the 2016 update of the ASAS/EULAR recommendations for the management of axial spondyloarthritis. RMD Open 2017;3:e000396.
    1. Haroon N, Inman RD, Learch TJ. et al. The impact of tumor necrosis factor α inhibitors on radiographic progression in ankylosing spondylitis. Arthritis Rheum 2013;65:2645–54.
    1. van der Heijde D, Baraliakos X, Hermann KA. et al. Limited radiographic progression and sustained reductions in MRI inflammation in patients with axial spondyloarthritis: 4-year imaging outcomes from the RAPID-axSpA phase III randomised trial. Ann Rheum Dis 2018;77:699–705.
    1. Machado P. Anti-tumor necrosis factor and new bone formation in ankylosing spondylitis: the controversy continues. Arthritis Rheum 2013;65:2537–40.
    1. Gensler LS, Reveille JD, Lee M. et al. High dose nonsteroidal anti-inflammatory drugs (NSAIDs) and tumor necrosis factor inhibitor use results in less radiographic progression in ankylosing spondylitis – a longitudinal analysis. In: ACR/AHRP Annual Meeting, Washington DC, 2016. Abstract 1956.
    1. Molnar C, Scherer A, Baraliakos X. et al. TNF blockers inhibit spinal radiographic progression in ankylosing spondylitis by reducing disease activity: results from the Swiss Clinical Quality Management cohort. Ann Rheum Dis 2018;77:63–9.
    1. Poddubnyy D, Protopopov M, Haibel H. et al. High disease activity according to the Ankylosing Spondylitis Disease Activity Score is associated with accelerated radiographic spinal progression in patients with early axial spondyloarthritis: results from the GErman SPondyloarthritis Inception Cohort. Ann Rheum Dis 2016;75:2114–8.
    1. van Tubergen A, Ramiro S, van der Heijde D. et al. Development of new syndesmophytes and bridges in ankylosing spondylitis and their predictors: a longitudinal study. Ann Rheum Dis 2012;71:518–23.
    1. Ramiro S, Landewé R, van Tubergen A. et al. Lifestyle factors may modify the effect of disease activity on radiographic progression in patients with ankylosing spondylitis: a longitudinal analysis. RMD Open 2015;1:e000153.
    1. Machado P, Landewé R, Braun J. et al. A stratified model for health outcomes in ankylosing spondylitis. Ann Rheum Dis 2011;70:1758–64.
    1. Viitanen JV, Kokko ML, Heikkilä S, Kautiainen H.. Neck mobility assessment in ankylosing spondylitis: a clinical study of nine measurements including new tape methods for cervical rotation and lateral flexion. Br J Rheumatol 1998;37:377–81.
    1. Viitanen JV, Kokko ML, Lehtinen K, Suni J, Kautiainen H.. Correlation between mobility restrictions and radiologic changes in ankylosing spondylitis. Spine (Phila Pa 1976) 1995;20:492–6.
    1. Kennedy LG, Jenkinson TR, Mallorie PA. et al. Ankylosing spondylitis: the correlation between a new metrology score and radiology. Br J Rheumatol 1995;34:767–70.
    1. Wanders A, Landewé R, Dougados M. et al. Association between radiographic damage of the spine and spinal mobility for individual patients with ankylosing spondylitis: can assessment of spinal mobility be a proxy for radiographic evaluation? Ann Rheum Dis 2005;64:988–94.
    1. Machado P, Landewé R, Braun J. et al. Both structural damage and inflammation of the spine contribute to impairment of spinal mobility in patients with ankylosing spondylitis. Ann Rheum Dis 2010;69:1465–70.
    1. Braun J, Golder W, Bollow M, Sieper J, van der Heijde D.. Imaging and scoring in ankylosing spondylitis. Clin Exp Rheumatol 2002;20 (6 Suppl 28):S178–84.
    1. Bochkova AG, Levshakova AV, Bunchuk NV, Braun J.. Spinal inflammation lesions as detected by magnetic resonance imaging in patients with early ankylosing spondylitis are more often observed in posterior structures of the spine. Rheumatology 2010;49:749–55.
    1. Braun J, Baraliakos X, Golder W. et al. Analysing chronic spinal changes in ankylosing spondylitis: a systematic comparison of conventional X rays with magnetic resonance imaging using established and new scoring systems. Ann Rheum Dis 2004;63:1046–55.
    1. Diekhoff T, Hermann KA, Greese J. et al. Comparison of MRI with radiography for detecting structural lesions of the sacroiliac joint using CT as standard of reference: results from the SIMACT study. Ann Rheum Dis 2017;76:1502–8.
    1. Bray TJP, Bainbridge A, Punwani S, Ioannou Y, Hall-Craggs MA.. Simultaneous quantification of bone edema/adiposity and structure in inflamed bone using chemical shift-encoded MRI in spondyloarthritis. Magn Reson Med 2018;79:1031–42.
    1. Tan S, Yao J, Flynn JA, Yao L, Ward MM.. Quantitative syndesmophyte measurement in ankylosing spondylitis using CT: longitudinal validity and sensitivity to change over 2 years. Ann Rheum Dis 2015;74:437–43.
    1. Braun J, Baraliakos X, Golder W. et al. Magnetic resonance imaging examinations of the spine in patients with ankylosing spondylitis, before and after successful therapy with infliximab: evaluation of a new scoring system. Arthritis Rheum 2003;48:1126–36.
    1. Haibel H, Rudwaleit M, Brandt HC. et al. Adalimumab reduces spinal symptoms in active ankylosing spondylitis: clinical and magnetic resonance imaging results of a fifty-two-week open-label trial. Arthritis Rheum 2006;54:678–81.
    1. Maksymowych WP, Inman RD, Salonen D. et al. Spondyloarthritis Research Consortium of Canada magnetic resonance imaging index for assessment of spinal inflammation in ankylosing spondylitis. Arthritis Rheum 2005;53:502–9.
    1. Lambert RGW, Pedersen SJ, Maksymowych W, Chiowchanwisawakit P, Ostergaard M.. Active inflammatory lesions detected by magnetic resonance imaging in the spine of patients with spondyloarthritis – definitions, assessment system, and reference image set. J Rheumatol 2009;36 (Suppl 84):3–17.
    1. de Bruin F, de Koning A, van den Berg R. et al. Development of the CT Syndesmophyte Score (CTSS) in patients with ankylosing spondylitis: data from the SIAS cohort. Ann Rheum Dis 2018;77:371–7.

Source: PubMed

Спонсоры и соавторы

Заболевания

Медикаментозные вмешательства

Подписаться